0001062993-23-012907.txt : 20230605 0001062993-23-012907.hdr.sgml : 20230605 20230605160325 ACCESSION NUMBER: 0001062993-23-012907 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230601 FILED AS OF DATE: 20230605 DATE AS OF CHANGE: 20230605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Toth Christopher A. CENTRAL INDEX KEY: 0001753950 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-04448 FILM NUMBER: 23992411 MAIL ADDRESS: STREET 1: 1252 COOLIDGE AVE. CITY: SAN JOSE STATE: CA ZIP: 95125 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BAXTER INTERNATIONAL INC CENTRAL INDEX KEY: 0000010456 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 360781620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE BAXTER PKWY STREET 2: DF2-1W CITY: DEERFIELD STATE: IL ZIP: 60015 BUSINESS PHONE: 8479482000 MAIL ADDRESS: STREET 1: ONE BAXTER PARKWAY STREET 2: DF2-1W CITY: DEERFIELD STATE: IL ZIP: 60015 FORMER COMPANY: FORMER CONFORMED NAME: BAXTER TRAVENOL LABORATORIES INC DATE OF NAME CHANGE: 19880522 FORMER COMPANY: FORMER CONFORMED NAME: BAXTER LABORATORIES INC DATE OF NAME CHANGE: 19760608 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0407 4 2023-06-01 0000010456 BAXTER INTERNATIONAL INC BAX 0001753950 Toth Christopher A. ONE BAXTER PARKWAY DEERFIELD IL 60015 0 1 0 0 EVP, Group Pres, Kidney Care 0 Common Stock, $1 par value 2023-06-01 4 A 0 106358 0 A 106358 D Mr. Toth received a grant of restricted stock units (RSUs)in connection with his appointment as EVP and Group President, Kidney Care. The RSUs are scheduled to vest in three equal annual installments beginning on June 3, 2024, the first anniversary of the grant date, subject to the terms and conditions set forth in the Baxter International Inc. 2021 Equity Plan. However, this award grant will vest in full if (i) by December 31, 2024, the proposed separation of the Kidney Care business (comprised of the Renal Care and Acute Therapies businesses) as a separately traded company (the "Business Transaction") does not occur; or (ii) in connection with the consummation of the Business Transaction, Mr. Toth is not appointed as Chief Executive Officer of the new company, Kidney Co. /s/ Matthew Rice, as attorney in-fact for Christopher A. Toth 2023-06-05